NVAX Q1 2020 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-15.2% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$23M-678.0% margin

Net Income

-$26M-765.9% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

-61.7%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$328M

Total Liabilities

$352M

Stockholders' Equity

-$24M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-15.2%
Gross Profit	$3M	$4M	-15.2%
Operating Income	-$23M	-$40M	+43.1%
Net Income	-$26M	-$43M	+40.2%

Revenue Segments

Grant

$3M100%